Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,812 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07249788RecruitingPhase 4
Resmetirom for MASH: A study on safety and effectiveness
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
Rawalpindi, Punjab ProvinceAges 18–75 - NCT07342803RecruitingPhase 2
LP-003 injection for allergic asthma
This trial tests an injection called LP-003 for people with allergic asthma that is not well controlled by current inhalers and other medications. It aims to see if the drug can improve asthma control and reduce flare-ups.
ShanghaiAges 18–75 - NCT07209033Recruiting
Testing FlexiOss for bone repair in leg and foot fractures
This trial tests a new material called FlexiOss to help heal broken bones in the leg or foot. It aims to see if the material is safe and effective for bone regeneration.
KrakowAges 18–75 - NCT07198139RecruitingPhase 1/Phase 2
Testing a new norovirus treatment in healthy adults
This trial tests an investigational medicine called CDI-988 to see if it can prevent or treat norovirus infection. Healthy adults will be intentionally exposed to a mild norovirus strain to see how the medicine works.
Decatur, GeorgiaAges 18–49 - NCT07260500RecruitingPhase 2
Growth hormone study for short children born small for gestational age
This trial tests a weekly growth hormone injection called PEG-rhGH to see if it helps short children born small for gestational age grow taller. It may be an option if your child has never taken growth hormone before and meets the height and age requirements.
Wuhan, HubeiAges 3 years+ - NCT05541822RecruitingPhase 2
Study drug for lung cancer with specific c-MET changes
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Lake City, FloridaAges 18 years+ - NCT07229950RecruitingPhase 2
Experimental tablet for moderate to severe Ulcerative Colitis
This trial tests an experimental tablet, HRS-7085, for people with moderate to severe Ulcerative Colitis who haven't gotten enough help from standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chengdu, SichuanAges 18–75 - NCT07382167RecruitingPhase 3
Study of Tenapanor for Chronic Constipation in Adults
This study tests an investigational drug called tenapanor for people with chronic idiopathic constipation (constipation with no clear cause). It aims to see if the drug can safely improve bowel movements in adults.
Foley, AlabamaAges 18–80 - NCT06735976Recruiting
Safety and effectiveness of LOBO device for PAVM treatment
This study tests a new device (LOBO™) to block abnormal blood vessels in the lungs called PAVMs. It is for people with HHT or similar conditions, and the device is placed into the vessel to reduce the risk of stroke or bleeding. You may be able to join if you have a suitable PAVM that is large enough and you are not taking blood thinners.
Chapel Hill, North CarolinaAges 14 years+ - NCT07453004RecruitingPhase 2
Study of plonmarlimab for frequent gout attacks
This trial tests a new investigational drug called plonmarlimab for people with frequent, painful gout flares who cannot take standard treatments. The goal is to see if it can reduce pain and inflammation from the flare.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07208058RecruitingPhase 3
Testing plonmarlimab for blood cell overactivation in people with rheumatic disease
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
Beijing, Beijing MunicipalityAges 16–80 - NCT07303777RecruitingPhase 2
Study of ABP-745 for people with atherosclerosis
This trial tests a new medication called ABP-745 to see if it helps people with atherosclerosis (hardening of the arteries). It is for people who are already taking a cholesterol-lowering medicine and who have had a special heart artery X-ray (coronary angiography).
Beverly Hills, CaliforniaAges 18–75 - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07204275RecruitingPhase 2/Phase 3
Testing povetacicept for primary membranous nephropathy
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Montgomery, AlabamaAges 18–75 - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Phoenix, ArizonaAges 2–17 - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07281833RecruitingPhase 3
Testing capivasertib with hormone therapy for advanced breast cancer
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
AnderlechtAges 18 years+ - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT07684235RecruitingPhase 3
Long-term study of a weight-loss drug for trial graduates
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
Daphne, AlabamaAges 18–99 - NCT07217067RecruitingPhase 2
Study of PKN605 for people with atrial fibrillation
This trial tests a new medicine called PKN605 for people with atrial fibrillation (irregular heartbeat). The goal is to see if it can safely help control heart rhythm. You will need to have had at least two AF episodes recently and meet other heart health criteria.
Tupelo, MississippiAges 18 years+ - NCT07288320RecruitingPhase 2
Testing NBI-1117568 for bipolar I mania
This trial tests an experimental drug called NBI-1117568 for people with bipolar I disorder who are currently having a manic or mixed episode. The goal is to see if the drug helps calm mania symptoms and is safe.
Little Rock, ArkansasAges 18–65 - NCT07448038RecruitingPhase 2
Study of selnoflast for heart artery inflammation
This trial tests a drug called selnoflast to see if it can reduce inflammation in the arteries of people with atherosclerosis (hardening of the arteries) who are at risk for heart attacks or other serious heart problems.
Beverly Hills, CaliforniaAges 18–80
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,812 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.